Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer

被引：8

作者：

Xiao, Yan ^{[1
,3
]}

Gao, Wencheng ^{[2
]}

机构：

[1] Dongguan Tungwah Hosp, Dept Oncol, Dongguan 523000, Guangdong, Peoples R China

[2] Dongguan Houjie Town Peoples Hosp, Dept Gen Surg, Dongguan 523962, Guangdong, Peoples R China

[3] Dongguan Tungwah Hosp, Dept Oncol, 1 Dongcheng East Rd, Dongguan 523000, Guangdong, Peoples R China

来源：

ONCOLOGY LETTERS | 2022年 / 24卷 / 01期

关键词：

triple-negative breast cancer; chemotherapy; platinum agents; poly(ADP-ribose) polymerase-inhibitors; immunotherapy; programmed cell death protein 1; programmed cell death 1 ligand 1 inhibitors; BRCA status; homologous recombination deficiency score; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; PLUS CARBOPLATIN; ADJUVANT BREAST; NAB-PACLITAXEL; HIGH-RISK; PHASE-II; CHEMOTHERAPY; WOMEN; IMPACT;

D O I：

10.3892/ol.2022.13340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is a heterogeneous disease, accounting for about 15.0-20.0% of all breast cancer cases. TNBC is associated with early recurrence and metastasis, strong invasiveness and a poor prognosis. Chemotherapy is currently the mainstay of treatment for TNBC, and achievement of a pathological complete response is closely associated with a long-term good prognosis. Improving the long-term prognosis in patients with TNBC is a challenge in breast cancer treatment, and more clinical evidence is needed to guide the choice of treatment strategies. The current study reviews the conventional treatment modality for TNBC and the selection of neoadjuvant chemotherapy (NACT) regimens available. The research progress on optimizing NACT regimens is also reviewed, and the uniqueness of the treatment of this breast cancer subtype is emphasized, in order to provide reference for the clinical practice and research with regard to TNBC treatment.

引用

页数：11

共 81 条

[71] Neoadjuvant treatment of breast cancer [J].

Thompson, A. M. ;

Moulder-Thompson, S. L. .

ANNALS OF ONCOLOGY, 2012, 23 :231-236

[72] PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project [J].

Tsao, Ming Sound ;

Kerr, Keith M. ;

Kockx, Mark ;

Beasley, Mary-Beth ;

Borczuk, Alain C. ;

Botling, Johan ;

Bubendorf, Lukas ;

Chirieac, Lucian ;

Chen, Gang i ;

Chou, Teh-Ying ;

Chung, Jin-Haeng ;

Dacic, Sanja ;

Lantuejoul, Sylvie ;

Mino-Kenudson, Mari ;

Moreira, Andre L. ;

Nicholson, Andrew G. ;

Noguchi, Masayuki ;

Pelosi, Giuseppe ;

Poleri, Claudia s ;

Russell, Prudence A. ;

Sauter, Jennifer ;

Thunnissen, Erik ;

Wistuba, Ignacio ;

Yu, Hui ;

Wynes, Murry W. ;

Pintilie, Melania ;

Yatabe, Yasushi ;

Hirsch, Fred R. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) :1302-1311

[73] Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial [J].

Tutt, Andrew ;

Tovey, Holly ;

Cheang, Maggie Chon U. ;

Kernaghan, Sarah ;

Kilburn, Lucy ;

Gazinska, Patrycja ;

Owen, Julie ;

Abraham, Jacinta ;

Barrett, Sophie ;

Barrett-Lee, Peter ;

Brown, Robert ;

Chan, Stephen ;

Dowsett, Mitchell ;

Flanagan, James M. ;

Fox, Lisa ;

Grigoriadis, Anita ;

Gutin, Alexander ;

Harper-Wynne, Catherine ;

Hatton, Matthew Q. ;

Hoadley, Katherine A. ;

Parikh, Jyoti ;

Parker, Peter ;

Perou, Charles M. ;

Roylance, Rebecca ;

Shah, Vandna ;

Shaw, Adam ;

Smith, Ian E. ;

Timms, Kirsten M. ;

Wardley, Andrew M. ;

Wilson, Gregory ;

Gillett, Cheryl ;

Lanchbury, Jerry S. ;

Ashworth, Alan ;

Rahman, Nazneen ;

Harries, Mark ;

Ellis, Paul ;

Pinder, Sarah E. ;

Bliss, Judith M. .

NATURE MEDICINE, 2018, 24 (05) :628-+

[74] Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial [J].

Untch, Michael ;

Jackisch, Christian ;

Schneeweiss, Andreas ;

Conrad, Bettina ;

Aktas, Bahriye ;

Denkert, Carsten ;

Eidtmann, Holger ;

Wiebringhaus, Hermann ;

Kuemmel, Sherko ;

Hilfrich, Joern ;

Warm, Mathias ;

Paepke, Stefan ;

Just, Marianne ;

Hanusch, Claus ;

Hackmann, John ;

Blohmer, Jens-Uwe ;

Clemens, Michael ;

Darb-Esfahani, Silvia ;

Schmitt, Wolfgang Daniel ;

Costa, Serban Dan ;

Gerber, Bernd ;

Engels, Knut ;

Nekljudova, Valentina ;

Loibl, Sibylle ;

von Minckwitz, Gunter .

LANCET ONCOLOGY, 2016, 17 (03) :345-356

[75] Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial [J].

von Minckwitz, Gunter ;

Schneeweiss, Andreas ;

Loibl, Sibylle ;

Salat, Christoph ;

Denkert, Carsten ;

Rezai, Mahdi ;

Blohmer, Jens U. ;

Jackisch, Christian ;

Paepke, Stefan ;

Gerber, Bernd ;

Zahm, Dirk M. ;

Kummel, Sherko ;

Eidtmann, Holger ;

Klare, Peter ;

Huober, Jens ;

Costa, Serban ;

Tesch, Hans ;

Hanusch, Claus ;

Hilfrich, Joern ;

Khandan, Fariba ;

Fasching, Peter A. ;

Sinn, Bruno V. ;

Engels, Knut ;

Mehta, Keyur ;

Nekljudova, Valentina ;

Untch, Michael .

LANCET ONCOLOGY, 2014, 15 (07) :747-756

[76] Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes [J].

von Minckwitz, Gunter ;

Untch, Michael ;

Blohmer, Jens-Uwe ;

Costa, Serban D. ;

Eidtmann, Holger ;

Fasching, Peter A. ;

Gerber, Bernd ;

Eiermann, Wolfgang ;

Hilfrich, Joern ;

Huober, Jens ;

Jackisch, Christian ;

Kaufmann, Manfred ;

Konecny, Gottfried E. ;

Denkert, Carsten ;

Nekljudova, Valentina ;

Mehta, Keyur ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) :1796-1804

[77] Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial [J].

Voorwerk, Leonie ;

Slagter, Maarten ;

Horlings, Hugo M. ;

Sikorska, Karolina ;

van de Vijver, Koen K. ;

de Maaker, Michiel ;

Nederlof, Iris ;

Kluin, Roelof J. C. ;

Warren, Sarah ;

Ong, Sufey ;

Wiersma, Terry G. ;

Russell, Nicola S. ;

Lalezari, Ferry ;

Schouten, Philip C. ;

Bakker, Noor A. M. ;

Ketelaars, Steven L. C. ;

Peters, Dennis ;

Lange, Charlotte A. H. ;

van Werkhoven, Erik ;

van Tinteren, Harm ;

Mandjes, Ingrid A. M. ;

Kemper, Inge ;

Onderwater, Suzanne ;

Chalabi, Myriam ;

Wilgenhof, Sofie ;

Haanen, John B. A. G. ;

Salgado, Roberto ;

de Visser, Karin E. ;

Sonke, Gabe S. ;

Wessels, Lodewyk F. A. ;

Linn, Sabine C. ;

Schumacher, Ton N. ;

Blank, Christian U. ;

Kok, Marleen .

NATURE MEDICINE, 2019, 25 (06) :920-+

[78]

Wolf DM, 2019, CANCER RES, V79, pS2679

[79] Tumor Mutational Burden and Response Rate to PD-1 Inhibition [J].

Yarchoan, Mark ;

Hopkins, Alexander ;

Jaffee, Elizabeth M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25) :2500-2501

[80]

Zgura Anca, 2018, Maedica (Bucur), V13, P317, DOI 10.26574/maedica.2018.13.4.317

← 1 2 3 4 5 6 7 8 9 →